Supernus Pharmaceuticals, Inc.
SUPNHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeSupernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United. The $2.77B market capitalization puts SUPN squarely in mid-cap range for its industry. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Market Cap
$2.77B
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
10.99
EPS (TTM)
$-0.52
EPS (Fwd)
$4.34
ROE
-2.8%
ROA
1.1%
Cash
$384.2M
Total Debt
$40.9M
Free CF
$132.6M
52W Change
42.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $384.2M in cash comfortably exceeding the $40.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $132.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -2.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.1% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $667.2M (2022) to $719.0M (2025).
The relatively low beta of 0.54 suggests SUPN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, SUPN has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Supernus Pharmaceuticals, Inc. and its sector.